Aradigm Corporation, a specialty pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Its proprietary programs under development include Liposomal Ciprofloxacin products, the anti-infective agents, which are used for the acute treatment of various bacterial infections, including exacerbations associated with pulmonary infections. The company?s Liposomal Ciprofloxacin products under development comprise ARD-3100 for the management of infections in cystic fibrosis patients; ARD-3100 and ARD-3150 for the management of infections in non-cystic fibrosis bronchiectasis patients; and ARD-1100 for the treatment of inhalation anthrax and other biodefense purposes. Its products also include ARD-1600 (Nicotine) for tobacco smoking cessation therapy. Aradigm Corporation has a license, development, and commercialization agreement with Lung Rx to develop and commercialize inhaled treprostinil using the company?s AERx Essence technology for the treatment of pulmonary arterial hypertension and other potential therapeutic indications. Aradigm Corporation was founded in 1991 and is based in Hayward, California.
Aradigm Corporation, a specialty pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Its proprietary programs under development include Liposomal Ciprofloxacin products, the anti-infective agents, which are used for the acute treatment of various bacterial infections, including exacerbations associated with pulmonary infections. The company?s Liposomal Ciprofloxacin products under development comprise ARD-3100 for the management of infections in cystic fibrosis patients; ARD-3100 and ARD-3150 for the management of infections in non-cystic fibrosis bronchiectasis patients; and ARD-1100 for the treatment of inhalation anthrax and other biodefense purposes. Its products also include ARD-1600 (Nicotine) for tobacco smoking cessation therapy. Aradigm Corporation has a license, development, and commercialization agreement with Lung Rx to develop and commercialize inhaled treprostinil using the company?s AERx Essence technology for the treatment of pulmonary arterial hypertension and other potential therapeutic indications. Aradigm Corporation was founded in 1991 and is based in Hayward, California.
Aradigm Corporation, a specialty pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Its proprietary programs under development include Liposomal Ciprofloxacin products, the anti-infective agents, which are used for the acute treatment of various bacterial infections, including exacerbations associated with pulmonary infections. The company?s Liposomal Ciprofloxacin products under development comprise ARD-3100 for the management of infections in cystic fibrosis patients; ARD-3100 and ARD-3150 for the management of infections in non-cystic fibrosis bronchiectasis patients; and ARD-1100 for the treatment of inhalation anthrax and other biodefense purposes. Its products also include ARD-1600 (Nicotine) for tobacco smoking cessation therapy. Aradigm Corporation has a license, development, and commercialization agreement with Lung Rx to develop and commercialize inhaled treprostinil using the company?s AERx Essence technology for the treatment of pulmonary arterial hypertension and other potential therapeutic indications. Aradigm Corporation was founded in 1991 and is based in Hayward, California.
USA 
Equity Search
Advanced Search
Filter Tops
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Profile
Volatility
History
News
Corporate Filings
Ownership Records
Discussion
3.70%
PLXT 
